JP2004536107A5 - - Google Patents

Download PDF

Info

Publication number
JP2004536107A5
JP2004536107A5 JP2003510065A JP2003510065A JP2004536107A5 JP 2004536107 A5 JP2004536107 A5 JP 2004536107A5 JP 2003510065 A JP2003510065 A JP 2003510065A JP 2003510065 A JP2003510065 A JP 2003510065A JP 2004536107 A5 JP2004536107 A5 JP 2004536107A5
Authority
JP
Japan
Prior art keywords
nucleic acid
agent
subunit
truncated
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003510065A
Other languages
English (en)
Japanese (ja)
Other versions
JP4221289B2 (ja
JP2004536107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/043151 external-priority patent/WO2003004055A2/en
Publication of JP2004536107A publication Critical patent/JP2004536107A/ja
Publication of JP2004536107A5 publication Critical patent/JP2004536107A5/ja
Application granted granted Critical
Publication of JP4221289B2 publication Critical patent/JP4221289B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003510065A 2000-11-27 2001-11-26 核酸アジュバント Expired - Fee Related JP4221289B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72431500A 2000-11-27 2000-11-27
PCT/US2001/043151 WO2003004055A2 (en) 2000-11-27 2001-11-26 Nucleic acid adjuvants

Publications (3)

Publication Number Publication Date
JP2004536107A JP2004536107A (ja) 2004-12-02
JP2004536107A5 true JP2004536107A5 (cg-RX-API-DMAC7.html) 2005-12-22
JP4221289B2 JP4221289B2 (ja) 2009-02-12

Family

ID=24909936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003510065A Expired - Fee Related JP4221289B2 (ja) 2000-11-27 2001-11-26 核酸アジュバント

Country Status (16)

Country Link
EP (1) EP1379273B1 (cg-RX-API-DMAC7.html)
JP (1) JP4221289B2 (cg-RX-API-DMAC7.html)
KR (1) KR20040045391A (cg-RX-API-DMAC7.html)
CN (1) CN1317034C (cg-RX-API-DMAC7.html)
AT (1) ATE442858T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001297988B2 (cg-RX-API-DMAC7.html)
BR (1) BR0115646A (cg-RX-API-DMAC7.html)
CA (1) CA2429708A1 (cg-RX-API-DMAC7.html)
DE (1) DE60139959D1 (cg-RX-API-DMAC7.html)
DK (1) DK1379273T3 (cg-RX-API-DMAC7.html)
ES (1) ES2332261T3 (cg-RX-API-DMAC7.html)
IL (2) IL156041A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03004638A (cg-RX-API-DMAC7.html)
NZ (1) NZ526175A (cg-RX-API-DMAC7.html)
PT (1) PT1379273E (cg-RX-API-DMAC7.html)
WO (1) WO2003004055A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035771A2 (en) 2003-10-10 2005-04-21 Powderject Vaccines, Inc. Nucleic acid constructs
ATE555127T1 (de) 2004-02-11 2012-05-15 Angeletti P Ist Richerche Bio Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
US8389686B2 (en) 2008-05-07 2013-03-05 Osaka University Noncovalent collagen crosslinking agent
AU2011302645B2 (en) 2010-09-15 2015-02-26 Applied Molecular Transport, Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CN103060253A (zh) * 2013-01-24 2013-04-24 麻丽丹 霍乱弧菌ctxAB基因的质粒克隆菌株以及制备方法和应用
EP3139965B1 (en) 2014-05-07 2021-09-29 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
PL3762009T3 (pl) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
ES2911075T3 (es) 2018-11-07 2022-05-17 Applied Molecular Transport Inc Constructos de administración para transcitosis y métodos relacionados
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
GB9416663D0 (en) 1994-08-17 1994-10-12 Oxford Bioscience Limited Particle delivery
DE69507321T2 (de) 1994-10-24 1999-07-15 Powderject Research Ltd., Oxford Nadellose spritze
GB9426379D0 (en) 1994-12-23 1995-03-01 Oxford Biosciences Ltd Particle delivery
US6056960A (en) * 1995-06-07 2000-05-02 Kaslow; Harvey R. Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization

Similar Documents

Publication Publication Date Title
EP1097213B1 (en) Vaccine against staphylococcus intoxication
US6977069B2 (en) Fusion proteins of Mycobacterium tuberculosis antigens and their uses
AU784131B2 (en) Methods for protecting against lethal infection with bacillus anthracis
JP2004527213A5 (cg-RX-API-DMAC7.html)
EP0919243A1 (en) Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
HU228354B1 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
US20080248068A1 (en) Use of Flagellin as an Adjuvant for Vaccine
US8834896B2 (en) Vault compositions for immunization
Wortham et al. Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2
AU8780798A (en) Vaccination by topical application of genetic vectors
US8143386B2 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
US7064195B2 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
JP4875497B2 (ja) バクテリオファージナノ粒子を含む方法および組成物
Mohapatra Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus
JP2002528123A5 (cg-RX-API-DMAC7.html)
Ali et al. Multiple Antigen Peptide Containing B and T Cell Epitopes of F 1 Antigen of Y ersinia pestis Showed Enhanced T h1 Immune Response in Murine Model
Leclerc et al. New approaches in vaccine development
Delman et al. Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer
JP2005512518A5 (cg-RX-API-DMAC7.html)
EP1954307A2 (en) Salmonella based oral vaccines for anthrax
TW528760B (en) Peptide repeat immunogens
García-Silva et al. Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity
EP0913157A1 (en) A new composite vaccine which contains antigen, antibody and recombinant dna and its preparing method
US20040082530A1 (en) Nucleic acid immunization
Xie et al. Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency